Rising Prevalence of Non-Small Cell Lung Cancer Has Propelled the Growth of the EGFR-NSCLC Market in the European Region!

The region’s emphasis on personalized medicine and precision oncology has fueled substantial investments in research and development, resulting in the emergence of innovative targeted therapies. The increasing availability of diagnostic tools has also contributed to earlier and more accurate patient identification. Further, the strong R&D initiatives from key players and funding from the government are some of the factors contributing to the growth of the market in the region. For instance, in 2021, the EU set out a USD 4.51 billion Beating Cancer plan, including the most concerted push ever for research and its translation through to better treatments.

Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=45923

Further,the European EGFR-NSCLC Market is expected to grow at a strong CAGR of 6.6% during the forecast period (2022-2030). Germany stands at the forefront of the EGFR-NSCLC market’s expansion, exemplifying noteworthy growth trends. The country’s renowned healthcare infrastructure, coupled with a thriving biopharmaceutical sector, has led to the development of cutting-edge therapies for EGFR-mutated NSCLC. German hospitals and research centers have played a pivotal role in clinical trials, fostering the introduction of novel treatments with impressive efficacy profiles. Additionally, the country’s robust health insurance system ensures patient access to these therapies, supporting market growth and encouraging ongoing advancements.

A report publishes some key points related to EGFR-NSCLC or lung cancer: –

• Approximately 70% of patients present with advanced-stage NSCLC. Or Approximately 10-15% of NSCLC patients in Europe have EGFR mutations.
• According to the research report, Each patient undergoing treatment costs the German health system 22400.95 USD (€20,400).

Europe EGFR-NSCLC Market Revenue (2020-2030) – USD Mn

• Based on drug type, the market is segmented into erlotinib, afatinib, gefitinib, osimertinib, and dacomitinib. The erlotinib category is to witness a considerable during the forecast period. Erlotinib, a first-generation EGFR tyrosine kinase inhibitor (TKI), has played a pivotal role in driving the EGFR-NSCLC market. It inhibits the activity of EGFR, effectively slowing down cancer cell growth and spread. Despite the emergence of newer agents, erlotinib remains a key treatment option, particularly for patients with EGFR-mutated NSCLC who have developed resistance to other therapies. The drug’s well-established efficacy and relatively favorable safety profile contribute to its continued significance in the market.
• On the basis of distribution channel, the market is categorized into online and offline. Among these, the online category held a significant share of the market in 2022. Online distribution channels enable patients to research treatment options, understand their condition, and connect with specialized healthcare professionals, regardless of geographical barriers. This virtual connectivity empowers patients and caregivers to make informed decisions and seek appropriate therapies, contributing to the expansion of the EGFR-NSCLC market.

Click here to view the Report Description & TOC https://univdatos.com/report/egfr-nsclc-market/

Global EGFR-NSCLC Market Segmentation

Market Insight, by Drug Type

Market Insights, by Distribution Channel

Market Insight, by Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• APAC
  • China
  • India
  • Japan
  • Rest of APAC
• Rest of the World

Top Company Profiles

• F. Hoffmann-La Roche Ltd
• Boehringer Ingelheim International GmbH
• AstraZeneca
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson Services, Inc.
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Genentech, Inc.
• Astellas Pharma Inc.